1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016

Summary

Global Markets Direct’s, ‘Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016’, provides an overview of the Takeda Pharmaceutical Company Limited’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Takeda Pharmaceutical Company Limited, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of Takeda Pharmaceutical Company Limited
- The report provides overview of Takeda Pharmaceutical Company Limited including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Takeda Pharmaceutical Company Limited’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Takeda Pharmaceutical Company Limited’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate Takeda Pharmaceutical Company Limited’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Takeda Pharmaceutical Company Limited
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Takeda Pharmaceutical Company Limited’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table Of Contents

Takeda Pharmaceutical Company Limited - Product Pipeline Review - 2016
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 6
Takeda Pharmaceutical Company Limited Snapshot 7
Takeda Pharmaceutical Company Limited Overview 7
Key Information 7
Key Facts 7
Takeda Pharmaceutical Company Limited - Research and Development Overview 8
Key Therapeutic Areas 8
Takeda Pharmaceutical Company Limited - Pipeline Review 15
Pipeline Products by Stage of Development 15
Pipeline Products - Monotherapy 16
Pipeline Products - Combination Treatment Modalities 17
Pipeline Products - Partnered Products 18
Pipeline Products - Out-Licensed Products 20
Takeda Pharmaceutical Company Limited - Pipeline Products Glance 22
Takeda Pharmaceutical Company Limited - Late Stage Pipeline Products 22
Takeda Pharmaceutical Company Limited - Clinical Stage Pipeline Products 25
Takeda Pharmaceutical Company Limited - Early Stage Pipeline Products 28
Takeda Pharmaceutical Company Limited - Drug Profiles 33
(alogliptin benzoate + metformin hydrochloride) 33
(alogliptin benzoate + pioglitazone hydrochloride) 35
brentuximab vedotin 38
ceftaroline fosamil 45
ixazomib citrate 48
ramelteon 53
vedolizumab 55
roflumilast 57
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) 62
azilsartan medoxomil 63
febuxostat XR 65
immune globulin (human) 66
pioglitazone hydrochloride 68
rasagiline mesylate 70
relugolix 71
TAK-003 72
vortioxetine hydrobromide 75
AM-4 78
DSM-265 79
namilumab 81
TAK-063 83
TAK-214 85
TAK-272 87
TAK-850 88
J-591 90
TAK-020 91
TAK-021 92
TAK-058 93
TAK-071 94
TAK-079 95
TAK-653 96
TAK-792 97
TAK-828 98
TAK-831 99
TAK-915 100
TAK-935 101
trelagliptin succinate 102
(plague + small pox) vaccine 104
BTZO-2 105
chikungunya vaccine 106
ELQ-300 107
influenza [strain A/H5N1] vaccine 108
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] (virus like particle) vaccine 109
mapatumumab 110
Monoclonal Antibody Conjugate to Target c-Ret for Breast Cancer 112
Monoclonal Antibody Conjugate to Target Guanylyl Cyclase C for Oncology 113
Monoclonal Antibody Conjugates for Oncology 114
respiratory syncytial virus (virus like particle) vaccine 115
Rotavirus (virus like particle) vaccine 116
Small Molecule 1 to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 117
Small Molecule 2 to Inhibit Gamma Secretase for Alzheimer's Disease 118
Small Molecule to Activate Glucokinase for Type 2 Diabetes 119
Small Molecule to Agonize Cannabinoid Receptor for Inflammatory Pain 120
Small Molecule to Agonize GPR52 for Psychiatry Disorders 121
Small Molecule to Antagonize Androgen Receptor for Prostate Cancer 122
Small Molecule to Antagonize CRF1 for CNS Disorders 123
Small Molecule to Antagonize Farnesoid X Receptor for Dyslipidemia 124
Small Molecule to Antagonize MCHR1 for Obesity 125
Small Molecule to Antagonize Mineralocorticoid Receptor for Hypertension 126
Small Molecule to Antagonize PDGFR and VEGFR-2 for Oncology 127
Small Molecule to Inhibit Dopamine Transporter, Noradrenaline Transporter and Serotonin Transporter for Depression 128
Small Molecule to Inhibit FAAH for Pain 129
Small Molecule to Inhibit Gamma Secretase for Alzheimer's Disease 130
Small Molecule to Inhibit HER2/EGFR for Oncology 131
Small Molecule to Inhibit NET for Stress Urinary Incontinence 132
Small Molecule to Inhibit PKC-Theta 133
Small Molecules for Parkinson's Disease 134
Small Molecules for Visceral Leishmaniasis 135
Small Molecules to Agonize GPR119 for Type II Diabetes 136
Small Molecules to Inhibit Acetyl-CoA Carboxylase for Obesity 137
Small Molecules to Inhibit B-Raf for Oncology 138
Small Molecules to Inhibit CENP-E for Colon Cancer 139
Small Molecules to Inhibit DPP-IV for Type 2 Diabetes 140
Small Molecules to Inhibit Hedgehog Signaling for Medulloblastoma 141
Small Molecules to Inhibit MAP2 for Obesity 142
Small Molecules to Inhibit MGAT2 for Metabolic Disorders 143
Small Molecules to Inhibit MMP-13 for Osteoarthritis 144
Small Molecules to Inhibit PARP-1 for Colon Cancer 145
Small Molecules to Inhibit TYK2 146
Stem Cell Therapy for Muscular Dystrophy 147
T-1840383 148
T-3256336 149
TAK-041 150
TAK-480 151
TAK-632 152
Y-443 153
Small Molecule for Undisclosed Indication 154
Small Molecule to Inhibit Arginine Methyltrasferase for Oncology 155
Small Molecule to Inhibit HDAC6 156
Small molecules for Leishmaniasis and Trypanosomiasis 157
Small Molecules for Malaria 158
Small Molecules for Tuberculosis 159
Small Molecules to Inhibit Apoptosis Signal-Regulating Kinase 1 160
Small Molecules to Inhibit FAK for Oncology 161
Small Molecules to Inhibit HER2 and EGFR for Oncology 162
Small Molecules to Inhibit IAP for Oncology 163
Small Molecules to Inhibit Mcl-1 and Bcl-xL for Oncology 164
Y-142 165
Takeda Pharmaceutical Company Limited - Pipeline Analysis 166
Takeda Pharmaceutical Company Limited - Pipeline Products by Target 166
Takeda Pharmaceutical Company Limited - Pipeline Products by Route of Administration 176
Takeda Pharmaceutical Company Limited - Pipeline Products by Molecule Type 177
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action 178
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates 188
Takeda Pharmaceutical Company Limited - Dormant Projects 232
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products 235
Discontinued Pipeline Product Profiles 237
Takeda Pharmaceutical Company Limited - Company Statement 246
Takeda Pharmaceutical Company Limited - Locations And Subsidiaries 247
Head Office 247
Other Locations and Subsidiaries 247
Appendix 257
Methodology 257
Coverage 257
Secondary Research 257
Primary Research 257
Expert Panel Validation 257
Contact Us 257
Disclaimer 258

List of Tables
Takeda Pharmaceutical Company Limited, Key Information 15
Takeda Pharmaceutical Company Limited, Key Facts 15
Takeda Pharmaceutical Company Limited - Pipeline by Indication, 2016 17
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016 23
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016 24
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016 25
Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016 26
Takeda Pharmaceutical Company Limited - Partnered Products/ Combination Treatment Modalities, 2016 27
Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016 28
Takeda Pharmaceutical Company Limited - Out-Licensed Products/ Combination Treatment Modalities, 2016 29
Takeda Pharmaceutical Company Limited - Pre-Registration, 2016 30
Takeda Pharmaceutical Company Limited - Filing rejected/Withdrawn, 2016 31
Takeda Pharmaceutical Company Limited - Phase III, 2016 32
Takeda Pharmaceutical Company Limited - Phase II, 2016 33
Takeda Pharmaceutical Company Limited - Phase I, 2016 34
Takeda Pharmaceutical Company Limited - Phase 0, 2016 35
Takeda Pharmaceutical Company Limited - IND/CTA Filed, 2016 36
Takeda Pharmaceutical Company Limited - Preclinical, 2016 37
Takeda Pharmaceutical Company Limited - Discovery, 2016 40
Takeda Pharmaceutical Company Limited - Pipeline by Target, 2016 174
Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016 184
Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016 185
Takeda Pharmaceutical Company Limited - Pipeline Products by Mechanism of Action, 2016 186
Takeda Pharmaceutical Company Limited - Recent Pipeline Updates, 2016 196
Takeda Pharmaceutical Company Limited - Dormant Developmental Projects,2016 240
Takeda Pharmaceutical Company Limited - Discontinued Pipeline Products, 2016 243
Takeda Pharmaceutical Company Limited, Other Locations 255
Takeda Pharmaceutical Company Limited, Subsidiaries 255

List of Figures
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Indication, 2016 17
Takeda Pharmaceutical Company Limited - Pipeline by Stage of Development, 2016 23
Takeda Pharmaceutical Company Limited - Monotherapy Products in Pipeline, 2016 24
Takeda Pharmaceutical Company Limited - Combination Treatment Modalities in Pipeline, 2016 25
Takeda Pharmaceutical Company Limited - Partnered Products in Pipeline, 2016 26
Takeda Pharmaceutical Company Limited - Out-Licensed Products in Pipeline, 2016 28
Takeda Pharmaceutical Company Limited - Pipeline by Top 10 Target, 2016 174
Takeda Pharmaceutical Company Limited - Pipeline by Route of Administration, 2016 184
Takeda Pharmaceutical Company Limited - Pipeline by Molecule Type, 2016 185
Takeda Pharmaceutical Company Limited - Pipeline Products by Top 10 Mechanism of Action, 2016 186

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.